Minoxidil Niosome Loaded Dissolving Microneedle Delivery System for Treatment of DHT Induced Androgenic Alopecia in C57BL/6 Mice

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

In this study, Rosa rugosa water extract improved hair length and thickness in a mouse model of DHT-induced alopecia by enhancing the expression of hair growth-promoting factors while inhibiting growth-suppressive proteins, suggesting its potential as a natural therapy for hair loss prevention.

In this meta-analysis, researchers found that oral and topical minoxidil treatments for androgenetic alopecia had similar efficacy in improving hair density and diameter, but oral minoxidil resulted in a higher incidence of hypertrichosis compared to topical use.

This review concludes that low-level laser therapy is the most supported physical treatment for androgenetic alopecia, but other therapies like nonablative laser treatments and combinations including PEMF may also be promising.

This review explores the use of topical and transdermal delivery for drugs and cosmetics, highlighting the benefits of avoiding side effects and rapid metabolism, with a focus on nanoparticulate formulations and techniques for studying skin penetration.

New microneedle method improves hair regrowth treatment delivery.

This review summarizes existing knowledge on androgenetic alopecia, including its epidemiology, pathophysiology, and management, but presents no new research findings.

This study found that combining minoxidil with ginsenosides Rg3 in a novel delivery system improved hair growth by reducing inflammation and oxidative stress in androgen alopecia treatments.

In this study, researchers developed a biodegradable microneedle made of hyaluronic acid, intended to enhance drug delivery through the skin's stratum corneum and potentially promote hair growth by overcoming the skin's barrier function in alopecia treatment.

This study found that ethosome-loaded minoxidil and tocopherol acetate improved hair regeneration and regulated the microenvironment around hair follicles better than commercial minoxidil in androgenic alopecia model mice, showing promise as a treatment strategy.

This study found that nanoparticles containing minoxidil and betamethasone improved drug delivery to hair follicles, with lipidic nanoparticles significantly enhancing minoxidil and betamethasone penetration compared to control, making them a promising option for alopecia areata treatment with reduced side effects.

This study found that a topical gel containing Minoxidil and Tofacitinib citrate showed promise for treating alopecia areata, with formulation F5 demonstrating effective drug release and stability in evaluations.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study developed a novel protocol that demonstrated improved localized delivery of minoxidil to eyebrow application sites with minimal runoff, compared to a control formulation.

In this study, the researchers developed minoxidil cubosomes using nanotechnology, which improved drug penetration in the skin, showed greater hair growth efficacy, and reduced adverse skin reactions compared to traditional minoxidil solutions.

This study reported that a curcumin-zinc microneedle patch improved hair regrowth and wound healing in animal models, suggesting potential as a versatile treatment for hair loss.

The researchers reported that caprylic acid effectively enhances the permeability and diffusion of minoxidil through rat skin compared to other penetration enhancers.

This study found that a transdermal drug delivery system using nanostructured lipid carriers and polymeric microneedles for β-sitosterol significantly enhanced hair growth in testosterone-induced alopecia rats, suggesting potential for treating androgenic alopecia.

In this study, researchers found that dissolving microneedles made with hyaluronic acid enhanced the effectiveness of minoxidil in reducing hair loss and promoting hair growth in alopecia-affected mice more effectively than topical minoxidil alone, while using only 10% of the drug amount.

This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This study suggests that combination therapies including minoxidil with either finasteride, low-level laser light therapy, or microneedling are more effective than minoxidil alone for treating androgenetic alopecia.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This study found that red ginseng oil and its major components improved hair regrowth in testosterone-treated mice by promoting an earlier anagen phase and altering related gene expressions.